| Primary |
| Adrenocortical Carcinoma |
47.8% |
| Adrenal Carcinoma |
14.5% |
| Adrenal Insufficiency |
6.4% |
| Hypertension |
6.0% |
| Hypothyroidism |
2.8% |
| Pituitary-dependent Cushing's Syndrome |
2.8% |
| Secondary Adrenocortical Insufficiency |
2.8% |
| Adrenal Gland Cancer Metastatic |
2.0% |
| Insomnia |
2.0% |
| Cushing's Syndrome |
1.6% |
| Hypercorticoidism |
1.6% |
| Nausea |
1.6% |
| Prophylaxis |
1.6% |
| Antibiotic Prophylaxis |
1.2% |
| Vitamin Supplementation |
1.2% |
| Abdominal Pain |
0.8% |
| Adrenal Gland Cancer |
0.8% |
| Cardiac Failure |
0.8% |
| Depression |
0.8% |
| Hormone Replacement Therapy |
0.8% |
|
| Vomiting |
12.9% |
| Weight Decreased |
10.8% |
| Death |
9.7% |
| Malignant Neoplasm Progression |
6.5% |
| White Blood Cell Count Decreased |
6.5% |
| Somnolence |
5.4% |
| Adverse Event |
4.3% |
| Dysphagia |
4.3% |
| Renal Failure |
4.3% |
| Accidental Exposure |
3.2% |
| Aplasia Pure Red Cell |
3.2% |
| Gamma-glutamyltransferase Increased |
3.2% |
| Hepatic Enzyme Increased |
3.2% |
| Hepatitis |
3.2% |
| Hepatitis Acute |
3.2% |
| Leukopenia |
3.2% |
| Overdose |
3.2% |
| Proteinuria |
3.2% |
| Respiratory Distress |
3.2% |
| Sleep Disorder |
3.2% |
|
| Secondary |
| Product Used For Unknown Indication |
56.4% |
| Adrenocortical Carcinoma |
9.3% |
| Drug Use For Unknown Indication |
7.1% |
| Hypertension |
4.4% |
| Contraception |
3.6% |
| Adrenocortical Insufficiency Acute |
3.1% |
| Pituitary-dependent Cushing's Syndrome |
3.1% |
| Adrenal Suppression |
1.8% |
| Chemotherapy |
1.8% |
| Adrenal Gland Cancer Metastatic |
1.3% |
| Cushing's Syndrome |
1.3% |
| Adrenal Insufficiency |
0.9% |
| Dyspepsia |
0.9% |
| Gastrointestinal Disorder |
0.9% |
| Hypertriglyceridaemia |
0.9% |
| Sleep Disorder |
0.9% |
| Thrombosis Prophylaxis |
0.9% |
| Addison's Disease |
0.4% |
| Adrenal Carcinoma |
0.4% |
| Anticoagulant Therapy |
0.4% |
|
| Cytolytic Hepatitis |
16.3% |
| Hepatitis Acute |
10.2% |
| Condition Aggravated |
8.2% |
| Fatigue |
8.2% |
| Liver Disorder |
8.2% |
| Toxic Skin Eruption |
8.2% |
| Alanine Aminotransferase Increased |
6.1% |
| Sleep Disorder |
6.1% |
| Adrenocortical Carcinoma |
4.1% |
| Gamma-glutamyltransferase Increased |
4.1% |
| Accidental Overdose |
2.0% |
| Cushing's Syndrome |
2.0% |
| Gastrointestinal Disorder |
2.0% |
| Hepatitis |
2.0% |
| Hypercholesterolaemia |
2.0% |
| Melanocytic Naevus |
2.0% |
| Memory Impairment |
2.0% |
| Pancreatitis Acute |
2.0% |
| Psychomotor Skills Impaired |
2.0% |
| Rash |
2.0% |
|
| Concomitant |
| Product Used For Unknown Indication |
41.7% |
| Cushing's Syndrome |
16.7% |
| Hypertension |
12.5% |
| Adrenocortical Carcinoma |
8.3% |
| Diabetes Mellitus |
8.3% |
| Chemotherapy |
4.2% |
| Hypercholesterolaemia |
4.2% |
| Osteoporosis |
4.2% |
|
| Hypotension |
20.0% |
| Depressed Level Of Consciousness |
10.0% |
| Electrocardiogram Qt Prolonged |
10.0% |
| Lung Neoplasm Malignant |
10.0% |
| Nausea |
10.0% |
| Rhabdomyolysis |
10.0% |
| Septic Shock |
10.0% |
| Syncope |
10.0% |
| Therapeutic Response Decreased |
10.0% |
|
